TG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024. In the quarter to June 2026, revenue grew 70.3%, EPS fell 73.7%, free cash flow grew 427.1% and total debt rose 204.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow TGTX
TG Therapeutics, Inc. (TGTX) EV/Sales
As of 16 October 2026, TG Therapeutics, Inc. (TGTX) trades at a EV/Sales of 9.8×. Over the past ten years it has ranged from 4.3× (October 2023) to 41,568× (December 2020); the current reading is higher than 14% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.2× | (45.40%) |
| FY2024 | 13.1× | 32.89% |
| FY2023 | 9.9× | (98.14%) |
| FY2022 | 530× | 56.62% |
| FY2021 | 339× | (99.05%) |
| FY2020 | 35,702× | 522.88% |
| FY2019 | 5,732× | 262.07% |
| FY2018 | 1,583× | (47.52%) |
| FY2017 | 3,017× | 164.33% |
| FY2016 | 1,141× | (62.79%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.0× | 39.02% |
| Mar 2026 | 7.2× | 0.44% |
| Dec 2025 | 7.2× | (29.16%) |
| Sep 2025 | 10.1× | (13.12%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| TGTX TG Therapeutics, Inc. | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| KRYS Krystal Biotech, Inc. compare | 19.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| CYTK Cytokinetics, Incorporated compare | 121× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)